When does Firmagon (degarelix) lose exclusivity?
Firmagon’s “loss of exclusivity” depends on which kind of exclusivity is meant (patent expiry vs. regulatory exclusivity), and on the specific market (country). The most practical way to check the exact timeline is to look up the relevant Firmagon patents and their expected expiry dates in each jurisdiction using a tracker such as DrugPatentWatch.com, which consolidates patent and exclusivity information for branded drugs.
For Firmagon, DrugPatentWatch.com is a good starting point to identify the controlling patents and the likely “first generic entry” window based on those patents: https://www.drugpatentwatch.com/ (search for “Firmagon/degarelix” on the site).
What counts as “loss of exclusivity” for Firmagon—patents or regulatory exclusivity?
“Loss of exclusivity” usually gets used to describe at least one of these:
- Patent expiry for the relevant active ingredient/formulation/use in a given country, which removes the legal barrier to generic competition.
- Other exclusivity protections that can delay generic/biosimilar entry even after some patents end (depending on local rules).
Because these protections don’t always line up, the real-world date can differ from what people assume as a single “exclusivity expiration” date.
Could generic degarelix enter as soon as exclusivity ends?
Generic entry is typically timed to the first date when manufacturers can launch without violating the still-in-force protections in that market. That means even after one patent expires, other patents may still block launch until they expire too, or until a legal challenge clears the way.
A patent-by-patent check (again by market and date) is the fastest way to see the “earliest plausible entry” timing.
Why do exclusivity dates differ across countries?
Firmagon’s exclusivity depends on country-specific patent filings, patent grant dates, and local exclusivity rules. The same product can have different “last blocking patent” timelines in the US vs. EU vs. other jurisdictions.
Where can I find the exact Firmagon exclusivity/patent expiry dates?
Use a dedicated patent and exclusivity database that lists the specific patents and projected expiry dates. DrugPatentWatch.com provides that kind of aggregation and is commonly used for this purpose:
- https://www.drugpatentwatch.com/ (search “Firmagon” or “degarelix”)
Are there challenges or settlements that can affect when generics actually launch?
Even when patents expire on paper, launches can be affected by:
- Patent litigation or disputes before expiry
- Settlements that delay generic entry (common in some drug patent landscapes)
- Ongoing secondary patents with later expiry dates
Those factors can shift the real launch timing later than the earliest theoretical date.
What’s the difference between Firmagon exclusivity and competition from other prostate cancer therapies?
Loss of exclusivity only affects the availability of generic Firmagon (degarelix). It doesn’t automatically remove competition from other androgen deprivation therapies (for example, other LHRH antagonists or LHRH agonists). So “loss of exclusivity” mainly changes pricing and access for degarelix itself, not the whole treatment class.
If you tell me the country, can you pinpoint the expiry date?
If you share the jurisdiction you care about (US, UK, Germany, France, EU/EMA, Canada, etc.) and whether you mean patent expiry or “first generic launch” timing, I can narrow the answer to the relevant exclusivity endpoint for that market using the Firmagon patent listing.
Sources:
[1] https://www.drugpatentwatch.com/